share_log

Small Biotechs Are Pulling Public Offerings, IPOs Amid 'Current Market Conditions'

Small Biotechs Are Pulling Public Offerings, IPOs Amid 'Current Market Conditions'

在 “当前市场状况” 中，小型生物技术公司正在撤回公开募股和首次公开募股
Benzinga Real-time News ·  2022/12/07 14:38
  • RNA biotech TransCode Therapeutics Inc (NASDAQ:RNAZ) withdrew its S-1 filing with the SEC that it made in late November.
  • TransCode said that the withdrawal reflects TransCode's belief that "current market conditions are not conducive for an offering on terms that would be in the best interests of the company's stockholders."
  • The lead candidate, dubbed TTX-MC138, is currently in the preclinical stage and is designed to treat metastatic cancers by inhibiting "microRNA-10b" to eliminate the metastasis.
  • TransCode believes that TTX-MC138 could be used as a treatment for many of these cancers, including breast, pancreatic, ovarian, colon, and glioblastomas.
  • Also see: TransCode Therapeutics Shares Shoot Higher After Encouraging Preclinical Data From Lead Cancer Candidate.
  • TransCode entered the stock market in July 2021, pricing its IPO at $4 a share and offering 6.25 million shares. However, it was planning to offer 2.8 million shares between $8-$10 a share.
  • Intrinsic Medicine and its blank-check partner Phoenix Biotech Acquisition Corp (NASDAQ:PBAX) terminated their reverse merger citing "current market conditions."
  • "After careful thought and consideration, we mutually determined that this action is in the best interest of all parties given current market conditions," stated Chris Ehrlich, CEO, and director of PBAX.
  • Price Action: RNAZ shares are up $112.8% at $0.90 on the last check Wednesday.
  • RNA生物技术公司TransCode Therapeutics Inc（纳斯达克股票代码：RNAZ）撤回了其在11月下旬向美国证券交易委员会提交的S-1申请。
  • TransCode表示，撤回反映了TransCode的信念，即 “当前的市场状况不利于以符合公司股东最大利益的条件进行发行。”
  • 这种名为 TTX-MC138 的主要候选药物目前处于临床前阶段，旨在通过抑制 “microRNA-10b” 来消除转移来治疗转移性癌症。
  • TransCode 认为，TTX-MC138 可以用作许多此类癌症的治疗方法，包括乳腺癌、胰腺癌、卵巢癌、结肠癌和胶质母细胞瘤。
  • 另请参阅： 在鼓励主要癌症候选者的临床前数据之后，TransCode Therapeutics股价飙升。
  • TransCode于2021年7月进入股票市场，其首次公开募股定价为每股4美元，发行625万股。但是，它计划发行280万股8至10美元之间的股票 一股。
  • Intrinsic Medicine及其空白支票合作伙伴菲尼克斯生物技术收购公司（纳斯达克股票代码：PBAX）以 “当前的市场状况” 为由终止了反向合并。
  • PBAX首席执行官兼董事Chris Ehrlich表示：“经过仔细思考和考虑，我们共同确定，鉴于当前的市场状况，这一行动符合各方的最大利益。”
  • 价格走势：在周三的最后一次支票中，澳大利亚央行股价上涨了112.8％，至0.90美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发